Bob G Gower bought $500k of ENSC
director at Ensysce Biosciences, Inc.. 357,143 shares at an average of $1.40, traded Dec 9, 2022, filed Feb 1, 2023.
Score components
- +15RoleDirector
- +18Trade size$500k at market
- +10Relative to holdingsHoldings up 90%
- +8Price context99% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-23-003343, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2022 | POpen-market purchase Common Stock | +357,143 | $1.40 | $500k | 753,095 | Feb 1, 2023 |
| Dec 9, 2022 | AGrant or award Warrantsderivative | +714,286 | - | - | 716,365 | Feb 1, 2023 |
Related signals
Other insiders at Ensysce Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $444k 908,614 shares | first purchase | |
| 37Weak | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $44k 90,287 shares | +8% | |
| 60Notable | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $182k 379,300 shares | +50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.